BioArctic: BMS deal a promising start for BBB-platform, Leqembi ramp up slower than expected - Redeye

Redeye return with a research update following BioArctic's Q1 report and capital markets day. We reiterate our positive long-term view but account for Eisai's latest Leqembi forecast and simulations as well as the weaker USD/SEK, leading to a slighly lower valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1110722/bioarctic-bms-deal-a-promising-start-for-bbb-platform-leqembi-ramp-up-slower-than-expected?utm_source=finwire&utm_medium=RSS